| Income Statement | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
| Research and development | 22,195 | 22,255 | 26,755* | 22,575 |
| General and administrative | 9,773 | 8,930 | 6,569* | 7,372 |
| Total operating expenses | 31,968 | 31,185 | 33,324 | 29,947 |
| Loss from operations | -31,968 | -31,185 | -33,324* | -29,947 |
| Interest income | 2,663 | 2,740 | 2,727* | 2,233 |
| Interest expense | 745 | 732 | 720* | 758 |
| Loss on extinguishment of debt | NaN | -488 | 0* | NaN |
| Other expenses, net | -177 | -87 | 271* | -280 |
| Total other income, net | 1,741 | 1,433 | 2,278* | 1,195 |
| Net loss before income taxes | -30,227 | -29,752 | -31,046* | -28,752 |
| Provision for income taxes | 0 | 0 | -717* | 239 |
| Net loss | -30,227 | -29,752 | -30,329* | -28,991 |
| Unrealized loss (gain) on available-for-sale investments | -299 | 46 | 1,251* | -240 |
| Total comprehensive loss | -30,526 | -29,706 | -29,078 | -29,231 |
| Basic EPS | -0.43 | 0.44 | -0.569 | 0.57 |
| Diluted EPS | -0.43 | 0.44 | -0.569 | 0.57 |
| Basic Average Shares | 69,724,761 | 67,263,234 | 51,141,247 | 51,097,711 |
| Diluted Average Shares | 69,724,761 | 67,263,234 | 51,141,247 | 51,097,711 |
enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc. (ENGN)